Cellosaurus HT-144 (CVCL_0318)

Cell line name HT-144
Synonyms HT 144; HT144; HT144-mel; HT144mel
Accession CVCL_0318
Resource Identification Initiative To cite this cell line use: HT-144 (RRID:CVCL_0318)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
From: Memorial Sloan-Kettering Cancer Center; New York; USA.
Registration: Memorial Sloan-Kettering Cancer Center Office of Technology Development; SK1980-544.
Microsatellite instability: Stable (MSS) (Sanger).
Sequence variation: BRAF p.Val600Glu (PubMed=15048078).
Sequence variation: Homozygous for a CDKN2A deletion (PubMed=9354451).
Omics: CNV analysis.
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Misspelling: HT-114; In Cosmic 929192.
Disease Melanoma (NCIt: C3224)
Derived from metastatic site: Subcutaneous.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Male
Category Cancer cell line
STR profile Source(s): ATCC; Cosmic-CLP

Markers:
AmelogeninX,Y
CSF1PO12
D13S31711,12
D16S53912,13
D5S81811,13
D7S82011
TH016,9
TPOX8,11
vWA16,18
Web pages http://faculty.washington.edu/trawets/archive/Human/skin/ht144/index.html
https://www.mskcc.org/research-advantage/support/technology/tangible-material/ht-144-human-melanoma-cell-line
Publications

DOI=10.1007/978-1-4757-1647-4_5
Fogh J., Trempe G.L.
New human tumor cell lines.
(In) Human tumor cells in vitro; Fogh J. (eds.); pp.115-159; Springer; New York (1975)

PubMed=327080; DOI=10.1093/jnci/59.1.221
Fogh J., Fogh J.M., Orfeo T.
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
J. Natl. Cancer Inst. 59:221-226(1977)

PubMed=833871; DOI=10.1093/jnci/58.2.209
Fogh J., Wright W.C., Loveless J.D.
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977)

PubMed=6935474; DOI=10.1093/jnci/66.2.239
Wright W.C., Daniels W.P., Fogh J.
Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.
J. Natl. Cancer Inst. 66:239-247(1981)

PubMed=7459858
Rousset M., Zweibaum A., Fogh J.
Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.
Cancer Res. 41:1165-1170(1981)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=9354451
Castellano M., Pollock P.M., Walters M.K., Sparrow L.E., Down L.M., Gabrielli B.G., Parsons P.G., Hayward N.K.
CDKN2A/p16 is inactivated in most melanoma cell lines.
Cancer Res. 57:4868-4875(1997)

PubMed=10338330; DOI=10.1097/00008390-199902000-00003
Rizos H., Darmanian A.P., Indsto J.O., Shannon J.A., Kefford R.F., Mann G.J.
Multiple abnormalities of the p16INK4a-pRb regulatory pathway in cultured melanoma cells.
Melanoma Res. 9:10-19(1999)

PubMed=14692828; DOI=10.1290/1543-706X(2004)40<35:COHMCL>2.0.CO;2
Quinones L.G., Garcia-Castro I.
Characterization of human melanoma cell lines according to their migratory properties in vitro.
In Vitro Cell. Dev. Biol. Anim. 40:35-42(2004)

PubMed=15048078; DOI=10.1038/sj.onc.1207563
Pavey S., Johansson P., Packer L., Taylor J., Stark M., Pollock P.M., Walker G.J., Boyle G.M., Harper U., Cozzi S.-J., Hansen K., Yudt L., Schmidt C., Hersey P., Ellem K.A.O., O'Rourke M.G.E., Parsons P.G., Meltzer P., Ringner M., Hayward N.K.
Microarray expression profiling in melanoma reveals a BRAF mutation signature.
Oncogene 23:4060-4067(2004)

PubMed=15467732; DOI=10.1038/sj.onc.1208152
Tanami H., Imoto I., Hirasawa A., Yuki Y., Sonoda I., Inoue J., Yasui K., Misawa-Furihata A., Kawakami Y., Inazawa J.
Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines.
Oncogene 23:8796-8804(2004)

PubMed=17363583; DOI=10.1158/0008-5472.CAN-06-4152
Stark M., Hayward N.
Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays.
Cancer Res. 67:2632-2642(2007)

PubMed=17516929; DOI=10.1111/j.1600-0749.2007.00375.x
Johansson P., Pavey S., Hayward N.
Confirmation of a BRAF mutation-associated gene expression signature in melanoma.
Pigment Cell Res. 20:216-221(2007)

PubMed=21654344; DOI=10.1097/CMR.0b013e328343a1d6
Molhoek K.R., Shada A.L., Smolkin M., Chowbina S., Papin J., Brautigan D.L., Slingluff C.L. Jr.
Comprehensive analysis of receptor tyrosine kinase activation in human melanomas reveals autocrine signaling through IGF-1R.
Melanoma Res. 21:274-284(2011)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

Cross-references
Cell line collections ATCC; HTB-63
Cell line databases/resources CCLE; HT144_SKIN
CGH-DB; 9314-4
Cosmic-CLP; 907067
GDSC; 907067
LINCS_LDP; LCL-1273
Ontologies BTO; BTO:0001406
CLO; CLO_0004280
EFO; EFO_0006443
MCCL; MCC:0000211
Biological sample resources BioSample; SAMN03472749
Chemistry resources ChEMBL-Cells; CHEMBL3308870
ChEMBL-Targets; CHEMBL2366291
Gene expression databases GEO; GSM162902
GEO; GSM219028
GEO; GSM887140
GEO; GSM888211
GEO; GSM1669912
Polymorphism and mutation databases Cosmic; 687436
Cosmic; 889003
Cosmic; 905227
Cosmic; 907067
Cosmic; 928717
Cosmic; 929192
Cosmic; 932999
Cosmic; 1022276
Cosmic; 1028800
Cosmic; 1102379
Cosmic; 1155271
Cosmic; 1477411
Cosmic; 2159445
Proteomic databases PRIDE; PXD002192